Both molecule types act as incretin receptor agonists, enhancing glucose-dependent insulin secretion, slowing gastric emptying and reducing intake. The dual agonist's lineage and the triple agonist's are closely related, and the discovery paper describes retatrutide as building on the dual design.
On these mechanisms the two are more alike than different.
Glucagon receptor agonism increases energy expenditure and hepatic fatty-acid oxidation and reduces hepatic fat, effects documented in physiology and in the rodent work. It also raises hepatic glucose output, which the incretin components must offset.
The rationale for the addition is that a molecule reducing intake and raising expenditure might outperform one acting on intake alone. That is the hypothesis; the mechanism alone does not prove the outcome.
The phase 2 trials compared retatrutide against placebo and, in one trial, against a GLP-1 receptor agonist. No published trial includes the dual agonist as an arm. Comparisons between the two therefore rest on separate trials in different populations with different designs, which is a weak basis.
Pages ranking the two have gone beyond what the literature supports. The accurate statement is that the triple agonist engages one more receptor, with the consequences described above, and that a direct comparison has not been published.
Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.
| Format | Strength | Price | Availability |
|---|---|---|---|
| Retatrutide Pack | 20 mg | AED 1010 | In stock |
Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.
Both molecule types act as incretin receptor agonists, enhancing glucose-dependent insulin secretion, slowing gastric emptying and reducing intake. The dual agonist's lineage and the triple agonist's are closely related, and the discovery paper describes retatrutide as building on the dual design.
No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.
Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.
Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.